Leprosy: current situation, clinical and laboratory aspects, treatment history and perspective of the uniform multidrug therapy for all patients
AUTOR(ES)
Cruz, Rossilene Conceição da Silva, Bührer-Sékula, Samira, Penna, Maria Lúcia F., Penna, Gerson Oliveira, Talhari, Sinésio
FONTE
An. Bras. Dermatol.
DATA DE PUBLICAÇÃO
2017-12
RESUMO
Abstract: In this review, the most relevant and current epidemiological data, the main clinical, laboratory and therapeutical aspects of leprosy are presented. Detailed discussion of the main drugs used for leprosy treatment, their most relevant adverse effects, evolution of the therapeutic regimen, from dapsone as a monotherapy to the proposed polychemotherapy by World Health Organization (WHO) can be found in this CME. We specifically highlight the drug acceptability, reduction in treatment duration and the most recent proposal of a single therapeutic regimen, with a fixed six months duration, for all clinical presentations, regardless of their classification.
Documentos Relacionados
- A clinical trial for uniform multidrug therapy for leprosy patients in Brazil: rationale and design
- Brazilian clinical trial of uniform multidrug therapy for leprosy patients: the correlation between clinical disease types and adverse effects
- Clinical trial for uniform multidrug therapy for leprosy patients in Brazil (U-MDT/CT-BR): adverse effects approach
- Leprosy: a review of laboratory and therapeutic aspects - Part 2
- Southern Cone Initiative for the elimination of domestic populations of Triatoma infestans and the interruption of transfusion Chagas disease: historical aspects, present situation, and perspectives